Last 46 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.44 | — | — | — | — | — | — | — | 0.13 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 72.65 | 285.42 | 9229.76 | 74.71 | 49.61 | — | 946.02 | 36.87 | 14.49 | 11.14 | 7.82 | 3.77 | 2.48 | 4.82 | 2.65 | 3.89 | 9.79 | 33.81 | 22.93 | 18.78 | 13.67 |
| — | — | +875.6% | +102.6% | +242.4% | — | +11993.5% | +877.4% | +483.3% | +131.1% | +195.7% | -3.0% | -74.6% | -85.7% | -88.5% | -79.3% | -28.4% | +94.6% | +179.4% | -96.2% | +21.5% | |
| P/B Ratio | 0.59 | 2.73 | 1.92 | 1.49 | 1.00 | 0.73 | 0.59 | 0.72 | 0.53 | — | 4.19 | 1.25 | 1.02 | 2.37 | 1.28 | 0.80 | 1.05 | 2.48 | 2.15 | 3.84 | 3.30 |
| — | +276.6% | +225.7% | +107.7% | +89.5% | — | -85.9% | -42.7% | -48.4% | — | +228.6% | +56.5% | -2.2% | -4.2% | -40.8% | -79.1% | -68.3% | -12.6% | -47.4% | +10.8% | +60.3% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | -27.7% | 100.0% | 100.0% | -544.5% | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| — | — | 0.0% | 0.0% | -644.5% | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Margin | -9390.8% | -6103.1% | -314219.0% | -2342.1% | -2014.8% | — | -29550.8% | -1155.7% | -780.1% | -337.5% | -1748.1% | -228.6% | -62.8% | -73.4% | -590.5% | -1017.8% | -3868.0% | -2429.0% | -1075.6% | -524.3% | -454.0% |
| — | — | -963.3% | -102.7% | -158.3% | — | -1590.5% | -405.5% | -1142.3% | -359.9% | -196.0% | +77.5% | +98.4% | +97.0% | +45.1% | -94.1% | -751.9% | -551.4% | -939.7% | +95.4% | -31.4% | |
| Net Margin | -22448.4% | -21772.3% | -740720.6% | -5306.3% | -5061.6% | — | -79956.0% | -2841.9% | 11171.9% | -1322.2% | -1861.7% | -798.5% | -424.0% | -480.6% | -616.4% | -1003.3% | -3938.4% | -2454.8% | -1113.0% | -527.6% | -472.5% |
| — | — | -826.4% | -86.7% | -145.3% | — | -4194.7% | -255.9% | +2734.7% | -175.1% | -202.0% | +20.4% | +89.2% | +80.4% | +44.6% | -90.2% | -733.5% | -685.1% | -853.6% | +95.7% | -30.6% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -93.2% | -42.5% | -34.3% | -23.9% | -23.7% | -16.4% | -11.6% | -12.9% | 228.4% | — | -112.3% | -52.0% | -52.5% | -53.6% | -56.8% | -55.5% | -72.9% | -39.0% | -29.2% | -24.2% | -25.3% |
| — | -159.4% | -194.6% | -85.6% | -110.4% | — | +89.6% | +75.2% | +535.4% | — | -97.7% | +6.3% | +28.0% | -37.5% | -94.2% | -129.4% | -188.4% | -160.7% | -108.8% | -26.1% | -64.6% | |
| ROA | -78.9% | -30.8% | -26.8% | -19.9% | -20.5% | -14.6% | -10.6% | -11.8% | 151.2% | -77.4% | -53.0% | -34.6% | -32.8% | -30.9% | -35.6% | -34.8% | -49.7% | -29.0% | -21.8% | -18.2% | -19.4% |
| — | -110.6% | -154.1% | -68.4% | -113.5% | +81.1% | +80.1% | +65.8% | +560.6% | -150.5% | -48.9% | +0.6% | +33.9% | -6.7% | -63.3% | -91.3% | -156.4% | -158.1% | -104.2% | -17.4% | -61.8% | |
| ROIC | -44.3% | -12.8% | -16.8% | -11.9% | -10.5% | -7.6% | -4.7% | -5.6% | -22.8% | — | — | — | — | — | — | — | — | — | — | — | — |
| — | -67.6% | -254.7% | -112.7% | +53.8% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.03 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.30 | 0.08 | 0.04 | 0.06 | 0.08 | 0.06 | 0.05 | 0.03 | 0.03 | 0.04 | 0.03 |
| — | +542.1% | +67.9% | +55.1% | +109.2% | — | -98.6% | -95.2% | -93.3% | — | +295.8% | +45.8% | -22.7% | +99.7% | +166.8% | +43.9% | +91.9% | +34.7% | -26.7% | +128.7% | +32.0% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 1.40 | 0.97 | 1.40 | 2.01 | 2.31 | 3.03 | 4.42 | 4.59 | 4.97 | 0.71 | 1.46 | 2.97 | 3.20 | 2.17 | 2.39 | 2.83 | 2.55 | 4.32 | 5.31 | 5.33 | 5.70 |
| — | -67.8% | -68.4% | -56.1% | -53.6% | +327.5% | +201.7% | +54.3% | +55.3% | -67.4% | -38.6% | +4.9% | +25.7% | -49.8% | -55.0% | -46.8% | -55.3% | -24.2% | -1.4% | -38.6% | -29.4% | |
| Quick Ratio | 1.40 | 0.97 | 1.40 | 2.01 | 2.31 | 3.03 | 4.42 | 4.59 | 4.97 | 0.71 | 1.46 | 2.97 | 3.20 | 2.17 | 2.39 | 2.83 | 2.55 | 4.32 | 5.31 | 5.33 | 5.70 |
| — | -67.8% | -68.4% | -56.1% | -53.6% | +327.5% | +201.7% | +54.3% | +55.3% | -67.4% | -38.6% | +4.9% | +25.7% | -49.8% | -55.0% | -46.8% | -55.3% | -24.2% | -0.6% | -38.6% | -29.4% | |
| Interest Coverage | -2825.35 | -557.99 | -3187.84 | -3340.59 | -2361.98 | -2686.71 | -799.69 | -2605.78 | -1685.07 | -1202.24 | -340.89 | -202.74 | -136.03 | -606.57 | -469.14 | -642.43 | -584.57 | -258.83 | -472.45 | -359.22 | -203.46 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 46 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ADXN stock.
Addex Therapeutics Ltd's current P/E is -0.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Addex Therapeutics Ltd's current operating margin is -9390.8%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Addex Therapeutics Ltd's business trajectory between earnings reports.